Skip to main content

Table 1 Clinical characteristics of study patients

From: Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

CharacteristicsRepaglinide and clopidogrel groupMitiglinide and clopidogrel groupRepaglinide groupp value
(N = 15)(N = 15)(N = 15)
Age75.6 ± 12.270.4 ± 11.576.1 ± 10.90.332*
Male (%)10 (66.7%)12 (80.0%)10 (66.7%)0.649***
BMI23.6 ± 3.224.4 ± 2.923.2 ± 3.90.598*
HbA1c9.3 ± 2.09.5 ± 2.09.7 ± 2.60.851*
Serum creatinine0.84 ± 0.320.80 ± 0.160.76 ± 0.160.594*
Liver function (Grade 1 [CTCAE ver.4.0]: AST, ALT, or T-Bil)4 (26.7%)5 (33.3%)3 (20.0%)0.912**
Calorie intake (kcal)1325.9 ± 283.31497.0 ± 247.51517.2 ± 168.70.065*
Concomitant agent use (oral hypoglycemic drugs, insulin, GLP-1 agonists, and/or agents which may enhance the hypoglycemic action of repaglinide or mitiglinide, other than the above)10 (67.7%)9 (60.0%)9 (60.0%)0.910***
  1. Mean ± S.D., * One-way analysis of variance, ** Fisher’s exact test, *** Chi-square test